Orexigen diet pill wins FDA panel backing (Reuters)
SILVER SPRING, Maryland (Reuter)-U. S. health adviser recommended beautiful first new weight lost in a decade on Tuesday, backing Contrave Orexigen Therapeutics Inc. Was of a trios drug addiction under the weight of the lost nine to come before regulators this year, the food and Drug Administration rejected the two rival medicine last October. THE FDA Panel of experts to be voted 13-7 who lost weight with benefits see Contrave Sur concern about that risk. THE FDA panel usually follow the recommendation. State-of-the-art led must pass 31 January. Shares of Orexigen was always totally immediately after the vote but reserve Arena pharmacy Inc. competitor was 7 percent higher in one commercial and Vivus Inc. rose 11 percent in extended trade. Put Contrave is key to companies based in California, which focuses only on obesity drug and not commodities. According to information of BioMedTracker Contrave, sales could reach $ 1. $ 2 billion by 2018. Face would be the biggest player in a u. s. ...